Crinetics Pharmaceuticals, Inc.

Welcome to the Krenetics Pharmacuticals first quarter 2024 earnings conference call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a question and answer session. I will now turn the call over to Corey Davis of LifeSci Advisors. Please go ahead.

Thank you, Alan. Hello, everyone, and welcome to Krenetics earnings call.

Joining me today are Dr. Scott Struthers, Founder and Chief Executive Officer, Dr. Alan Krasner, Chief Endocrinologist, and Mark Wilson, Chief Financial Officer. Also joining us for the Q&A portion of the call are Dr. Dana Pizzuti, Chief Medical and Development Officer, and Jim Hazard, Chief Commercial Officer. The press release announcing the first quarter 2024 financial results was issued today and is also available on the Crenetics corporate website. As a reminder, we'll be making forward-looking statements, and I invite you to learn about the risk and uncertainties associated with these statements as disclosed in our SEC filings. Such forward-looking statements are not a guarantee of performance, and the company's actual results could differ materially from those stated or implied in such statements due to risks and uncertainties associated with the company's businesses. These forward-looking statements are qualified in their entirety by the cautionary statements contained in today's news release, the company's other news releases, and Cronetic's SEC filings, including its annual report on Form 10-K. I'd also like to specify that the content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 9th, 2024. Chronetics takes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call.